B

Brawn Biotech Limited

BRAWN
Market snapshot · 2026-08-10 17:47 UTC

20.21

+₹0.96 (+4.99%)

MARKET CAP

₹6.06 Cr

STOCK P/E

6.2x

52W HIGH

₹24.37

52W LOW

₹16.66

BOOK VALUE

₹14.50

EPS

₹3.26

ROE

24.43%

SECTOR

Health Care

DEBT/EQUITY

VOLUME

360

P/B RATIO

1.39x

PEG RATIO

Sector

Health Care

Themes

Pharmaceuticals
₹23.40₹22.05₹20.71₹19.36₹18.01VolumeAug '25Sep '25Nov '25Jan '26Mar '26Apr '26Jun '26Aug '26

AI Summary

✦ Clartha

Valuation Metrics

Trading 7.1% below historical median. Valuation is stable — currently in the undervalued zone (z-score: -0.55). Confidence: 50%.

Forward Valuation Outlook

Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.

P/E
Undervalued

5Y Average

6.07

Current

5.90

Overvalued

7.30

Undervalued

5.39

P/S
Fair

5Y Average

0.35

Current

0.36

Overvalued

0.40

Undervalued

0.30

P/B
Strongly Undervalued

5Y Average

1.63

Current

1.39

Overvalued

1.88

Undervalued

1.39

Peers & Comparison

No peer data available for this company.
WHY THESE PEERS

No sector data available for this company.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹1.98 CrMar 2026

Latest net profit

₹0.58 CrMar 2026

Latest EPS

₹1.93Mar 2026

Net margin

-25.8%Mar 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %
Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26-27.0%-18.0%-9.0%0.0%9.0%-2.00 Cr0.00 Cr2.00 Cr4.00 Cr6.00 Cr
  • Revenue
  • Net income
  • Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share
Q4 '25Q1 '26Q2 '26Q3 '26Q4 '260.00 Cr2.00 Cr4.00 Cr6.00 Cr8.00 Cr₹-2₹-1₹0₹1₹2
  • Revenue
  • EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore
RevenueExpensesDepreciationOtheradjustmentsOperatingprofitOther incomeInterestOtheradjustmentsProfitbefore taxTax & otherOtheradjustmentsNet Profit-2.00 Cr-1.00 Cr0.00 Cr1.00 Cr2.00 Cr

Latest reported period: Mar 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore
Annual view
Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-7.00 Cr0.00 Cr7.00 Cr14 Cr21 Cr
  • Debt
  • Free cash flow
  • Cash & equivalents

Results

MetricMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +4.757.292.922.843.454.063.303.842.265.804.894.311.98
Expenses +4.887.453.313.423.844.563.624.242.815.624.884.322.49
Operating Profit-0.13-0.16-0.39-0.58-0.39-0.50-0.32-0.40-0.550.180.01-0.01-0.51
OPM %-2.74%-2.19%-13.36%-20.42%-11.30%-12.32%-9.70%-10.42%-24.34%3.10%0.20%-0.23%-25.76%
Other Income +0.000.000.000.000.080.000.000.000.090.090.090.090.18
Interest0.000.000.000.000.000.000.000.000.000.000.000.000.00
Depreciation0.040.020.030.030.030.030.030.030.030.030.030.030.03
Profit before tax-0.17-0.18-0.42-0.61-0.34-0.53-0.35-0.43-0.490.240.070.05-0.36
Tax %258.82%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-261.11%
Net Profit +-0.61-0.17-0.42-0.61-0.34-0.53-0.34-0.43-0.490.240.070.050.58
EPS in Rs-2.03-0.57-1.40-2.03-1.13-1.77-1.13-1.43-1.630.800.230.171.93
Raw PDF

All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).

Shareholding Pattern

HolderJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters +53.66%53.66%53.39%52.94%52.94%
DIIs +0.35%0.35%0.35%0.35%0.35%
Public +46.00%45.99%46.27%46.72%46.72%
Jun 2026
Promoters +
DIIs +
Public +

Events Timeline

Board Meeting Intimation for Consideration And Approval Of, Inter Alia, The Un-Audited Financial Results Of The Company For The Quarter Ended June 30, 2026.

Aug 05, 2026PDFCompany Reports Open

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Jul 08, 2026PDFCompany Reports Open

Closure of Trading Window

Jun 25, 2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Newspaper Publication

May 30, 2026PDFCompany Reports Open

Intimation Regarding Non-Applicability Of Regulation 23(9)

May 30, 2026PDFCompany Reports Open